Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

Current share price of US$483 suggests Vertex Pharmaceuticals is potentially 44% undervalued Analyst price target for VRTX is US$509 which is 40% below our fair value estimate ...

Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly ...